白雲山和黃中藥中成藥智造基地動工 預計2024年投產
廣州白雲山和記黃埔中藥有限公司中成藥智能製造及倉儲物流平臺一期項目,在白雲區鍾落潭鎮廣藥工業園日前正式動工建設,計劃於2024年年底正式交付使用。
白雲山和黃中藥總經理徐科一表示,一期項目配建倉庫將搭載智能立體倉庫系統與智慧物流信息系統,標誌着白雲山和黃中藥正式啓動企業數字化變革創新,以數字化引領企業智能化、產業化升級。
據悉,該項目擬打造成爲行業內中成藥智能製造的標杆基地以及行業領先的藥品倉儲物流平臺,與該公司亳州生產基地共同形成中藥成品智能製造南北「雙翼」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.